Akkermansia / CXCc Cancer Research Results

Akk, Akkermansia: Click to Expand ⟱
Features: Bacteria
Akkermansia improves cancer immunotherapy.
Gram-negative anaerobic bacterium of the phylum Verrucomicrobia.
Akkermansia muciniphila is a typical member of the human gut microbiome.

Akkermansia — a gut-resident, Gram-negative, obligate anaerobic bacterium (phylum Verrucomicrobia), most commonly referring to Akkermansia muciniphila, a mucin-degrading keystone member of the human intestinal microbiome. It is best classified as a microbiome agent (commensal taxon; “next-generation probiotic” / live biotherapeutic concept, strain-dependent), commonly abbreviated Akk or A. muciniphila. In oncology, Akkermansia is primarily positioned as a predictive biomarker and a mechanistic adjunct for immune checkpoint inhibitor (ICI) responsiveness rather than a cytotoxic drug, with multiple human cohorts linking baseline abundance to improved anti–PD-1/PD-L1 outcomes and early-stage clinical development of strain-specific products.

Primary mechanisms (ranked):

  1. Microbiome-mediated potentiation of anti-tumor immunity and ICI responsiveness via antigen-presenting cell programming and Th1/CD8 effector support (strain- and context-dependent).
  2. Reinforcement of gut barrier function through mucin-layer remodeling and epithelial tight-junction support, reducing pathologic translocation signals that can suppress systemic immunity.
  3. Microbial metabolite signaling (SCFA and bile-acid–linked axes; immunometabolic crosstalk) that can bias toward less inflammatory, more effective anti-tumor immune tone (context-dependent).

Bioavailability / PK relevance: Not a systemically distributed small molecule; exposure is primarily intraluminal (colon) with host effects mediated by epithelial/immune sensing and downstream systemic immune-metabolic signaling. Translation is strain-, viability-, formulation-, and colonization-dependent; “pasteurized” (non-viable) preparations can retain bioactivity for some non-oncology endpoints.

In-vitro vs systemic exposure relevance: Not concentration-driven in plasma; mechanistic claims should be interpreted through ecological/host-response readouts (engraftment, relative abundance, metabolomics, immune phenotyping) rather than micromolar cellular dosing.

Clinical evidence status: Human evidence is strongest for association/prediction of ICI benefit (observational cohorts, including prospective validation) and for feasibility/safety in non-cancer metabolic trials; interventional oncology evidence is emerging (early-phase live biotherapeutic/oncobiotic studies and microbiome modulation strategies), not an approved cancer therapy.

Summary:
-Can significantly inhibit carcinogenesis and improve anti-tumor effects, thus increasing the effectiveness of cancer immunotherapy.
-Enhanced abundance of Akkermansia in the intestine of those who responded positively to the ICI(immune checkpoint inhibitors).

-plausible general guidance: Eat fermented foods then fibre to maintain them. Fruits and vegs for fibre Chicory root for fibre (inulin which is main prebiotic).

• Akkermansia muciniphila specializes in degrading mucin, the glycoprotein component of the mucus layer lining the gut.

• Early clinical findings suggest that higher levels of Akkermansia correlate with improved responses to immune checkpoint inhibitors in cancer therapy.(e.g., anti-PD-1/PD-L1 therapy).

Akkermansia, and in particular Akkermansia muciniphila, is a key gut bacterium implicated in supporting intestinal health, modulating immune responses, and influencing metabolic balance. Its roles in enhancing gut barrier integrity, reducing inflammation, and possibly improving responses to cancer immunotherapy make it an attractive target for probiotic development and microbiome-based interventions. Although not a drug in itself, Akkermansia’s potential as a biomarker and therapeutic adjunct offers promising avenues for integrative approaches in precision medicine and cancer care.

Mechanistic axes for Akkermansia relevant to cancer translation

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ICI response support via APC–IL-12–Th1 and CD8 effector priming ↔ (indirect) ↑ anti-tumor immune competence G Immunotherapy sensitization Human cohorts repeatedly associate fecal Akk abundance with improved anti–PD-1 outcomes; preclinical work supports causality in ICI contexts (strain- and host-context dependent).
2 T cell trafficking and effector tone ↑ immune infiltration pressure ↑ CD8+ and CXCR3-related trafficking signals (context-dependent) G Improved immune tumor control Typically framed as improved “immune set-point” rather than a direct tumor-cell pathway modulation.
3 Gut barrier integrity and mucin ecology ↔ (indirect) ↑ mucus layer and epithelial barrier function; ↓ endotoxemia signals (context-dependent) G Reduced immunosuppressive systemic inflammation Mucin degradation is coupled to mucus turnover and can associate with improved barrier metrics in several models; translation depends on diet, baseline microbiome, and strain biology.
4 Microbial metabolites and immunometabolism ↔ (indirect) ↔ / ↑ regulatory-beneficial signaling (context-dependent) G Immune-metabolic tuning Likely mediated through community-level shifts (cross-feeding, SCFA/bile-acid networks) rather than Akk alone; directionality can vary by cancer type and treatment.
5 Clinical Translation Constraint — — — Deliverability and generalizability limits Strain specificity; formulation/viability; engraftment variability; antibiotic exposure; diet/fiber dependence; endpoints often correlative; oncology interventional evidence still early-phase.


CXCc, CXC chemokine family: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
(Prev called GRO1 oncogene)(KC) belongs to the CXC
The chemokine ligand 1 (CXCK1) is a small peptide belonging to the CXC chemokine family that acts as a chemoattractant for several immune cells, especially neutrophils or other non-hematopoietic cells to the site of injury or infection and plays an important role in regulation of immune and inflammatory responses.
CXCL1 is increased in ovarian cancer via GRB2-associated binding protein 2-dependent autocrine way, promoting tumour cells proliferation and angiogenesis;
Keratinocyte-derived chemokine (KC) belongs to the CXC family and it is homologous to interleukin (IL)-8.
The CXC chemokines can be further divided into two main subgroups based on the presence or absence of the ELR (Glu-Leu-Arg) motif:
1. ELR+ CXC Chemokines: These include chemokines such as CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8 (IL-8), and CXCL12 (SDF-1). They are primarily involved in promoting angiogenesis, recruiting neutrophils, and facilitating tumor growth.
2. ELR- CXC Chemokines: This subgroup includes chemokines like CXCL4, CXCL9, CXCL10, and CXCL11. These chemokines are often associated with anti-tumor immunity and can attract T cells and other immune cells to the tumor microenvironment.
CXC chemokines, particularly the ELR+ subset, can promote tumor growth by enhancing angiogenesis. CXC chemokines are involved in the metastatic spread of cancer cells. For example, CXCL12 and its receptor CXCR4 are known to play significant roles in the migration of cancer cells to distant sites, such as the bone marrow and lymph nodes.
Given their roles in cancer progression, CXC chemokines and their receptors are being investigated as potential therapeutic targets.


Scientific Papers found: Click to Expand⟱
542- Akk,  immuno,    Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
CD4+↑, CXCc↑, PD-1↝,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Immune & Inflammatory Signaling ⓘ

CD4+↑, 1,   CXCc↑, 1,   PD-1↝, 1,  
Total Targets: 3

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: CXCc, CXC chemokine family
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:26  Target#:72  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page